Exploring the potential new way of risk prediction in heart diseases

The potential to improve primary prevention by using brain natriuretic peptide (BNP) as an indicator of silent 'pancardiac' target organ damage

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN62172102

Enrollment

300

Registered

2008-06-26

Start date

2008-02-18

Completion date

Unknown

Last updated

2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular diseases Circulatory System N/A

Interventions

This is an observational cohort study where participants will undergo standard diagnostic tests but no pharmacological, surgical or lifestyle interventions will be made. Study 1: What

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Both males and females, age >50 2. Treated hypertensive and/or hypercholestrolemic 3. Primary prevention only i.e. no known ischaemic heart disease, cerebrovascular disease, heart failure or peripheral vascular disease

Exclusion criteria

Exclusion criteria: 1. Renal impairment 2. Obvious cause for raised BNP level e.g., valvular disease or arrhythmias

Design outcomes

Primary

Measure	Time frame
Study 1: The spectrum of cardiac target organ damage seen in those with an elevated BNP level Study 2: Proportion of participants with elevated BNP in the absence of ischaemia, LVH or LAD who develop LVH or LAD at four years	—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026